Literature DB >> 9310497

Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease.

M Chhanabhai1, S Krajewski, M Krajewska, H G Wang, J C Reed, R D Gascoyne.   

Abstract

The Caenorhabditis elegans cell death gene, Ced-3, encodes a protein homologous to mammalian interleukin-1beta-converting enzyme (ICE), a cysteine protease implicated in programmed cell death (PCD). CPP32, also known as Yama, apopain, and Caspase-3, is a member of this family, has substrate specificities similar to Ced-3, and has been shown to have an active role in PCD. Evidence suggests that these proteases act downstream of inhibitors of PCD such as Bcl-2 and Bcl-x(L), which are frequently expressed in Reed-Sternberg (RS) cells of Hodgkin's disease (HD). To date there have been no studies examining the role of the ICE/Ced-3 family of proteins, in particular CPP32, in HD. We examined 24 cases of HD with a classical immunophenotype and 6 cases of nodular lymphocyte predominant HD (NLPHD) for the expression of CPP32 in the RS cells and lymphohistiocytic (L&H) cells as detected by immunohistochemistry. Twenty two of 24 cases (92%) of HD expressed the protein in the RS cells, whereas the L&H cells in all 6 cases of NLPHD lacked expression of CPP32. These results provide further evidence that NLPHD is a phenotypically different disease distinct from classical forms of HD. The differential expression of the cell death protein CPP32 may be an important factor contributing to the apparently different clinical behaviour of NLPHD in contrast to classical HD. The lack of expression of CPP32 in NLPHD shares similarities with low-grade B-cell non-Hodgkin's lymphomas and may explain their common clinical course. Further studies are required to elucidate the significance of CPP32 in HD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310497

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.

Authors:  Horst Dürkop; Burkhard Hirsch; Corinna Hahn; Harald Stein
Journal:  J Mol Med (Berl)       Date:  2005-11-25       Impact factor: 4.599

2.  Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21(WAF1) expression and hepatic apoptosis.

Authors:  Bao-Hua Sun; Jun Zhang; Bao-J Wang; Xi-Ping Zhao; You-Kun Wang; Zhi-Qun Yu; Dong-Liang Yang; Lian-Jie Hao
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

3.  Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease.

Authors:  K F Izban; T Wrone-Smith; E D Hsi; B Schnitzer; M E Quevedo; S Alkan
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

4.  Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.

Authors:  Matthew W Boudreau; Jessie Peh; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2019-07-16       Impact factor: 5.100

Review 5.  Lymphocyte predominant Hodgkin's disease.

Authors:  Bradley C Ekstrand; Sandra J Horning
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

6.  Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion.

Authors:  M Vakkala; P Pääkkö; Y Soini
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

7.  Detection of apoptosis and expression of apoptosis-associated proteins as early predictors of prognosis after irradiation therapy in stage IIIb uterine cervical cancer.

Authors:  H Yuki; M Fujimura; Y Yamakawa; T Hidaka; S Saito
Journal:  Jpn J Cancer Res       Date:  2000-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.